Cargando…
Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs
BACKGROUND: Shuanghuang Shengbai granule is effective in curing cyclophosphamide-induced myelosuppression without promoting lung cancer development. This study aims to investigate its mechanism and therapeutic targets. METHODS: Nude mice with lung cancer were treated with physiological saline (contr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617494/ https://www.ncbi.nlm.nih.gov/pubmed/28977934 http://dx.doi.org/10.18632/oncotarget.19129 |
_version_ | 1783267000504549376 |
---|---|
author | Wang, Shuang Xu, Zhenye Wang, Lifang |
author_facet | Wang, Shuang Xu, Zhenye Wang, Lifang |
author_sort | Wang, Shuang |
collection | PubMed |
description | BACKGROUND: Shuanghuang Shengbai granule is effective in curing cyclophosphamide-induced myelosuppression without promoting lung cancer development. This study aims to investigate its mechanism and therapeutic targets. METHODS: Nude mice with lung cancer were treated with physiological saline (control), cyclophosphamide, or cyclophosphamide + Shuanghuang Shengbai. MicroRNA microarray was used to investigate the differentially expressed microRNAs in lung cancer stem cells or bone marrow hematopoietic stem cells between the three groups. MicroRNA expressions were confirmed using quantitative real time-polymerase chain reaction. RESULTS: Cyclophosphamide suppressed tumor growth and decreased the ratio of SP(+) lung cancer stem cells (P<0.05). Shuanghuang Shengbai further decreased the ratios of SP(+) and CD24(+)IGF1R(+) lung cancer stem cells (P<0.05). Shuanghuang Shengbai completely reversed the cyclophosphamide-induced decreases in white blood cells, proliferation index of bone marrow cells, and the ratio of CD34(+)SCA1(+) bone marrow hematopoietic stem cells (P<0.05). We found 45 and 343 altered microRNAs for SP(+) lung cancer stem cells and CD34(+)SCA1(+) bone marrow hematopoietic stem cells, respectively. Moreover, miR-32*, miR-466i-5p, and mmu-miR-669c in SP(+) lung cancer stem cells were confirmed, as well as mmu-miR-106b*, mmu-miR-144, mmu-miR-669k*, mmu-miR-142-3p, mmu-miR-210, and mmu-miR-223 in CD34(+)SCA1(+) bone marrow hematopoietic stem cells. CONCLUSION: Shuanghuang Shengbai might promote the proliferation of CD34(+)SCA1(+) bone marrow hematopoietic stem cells via up-regulating mmu-miR-106b*, mmu-miR-144, and mmu-miR-669k*, as well as down-regulating mmu-miR-142-3p, mmu-miR-210, and mmu-miR-223. Shuanghuang Shengbai might further inhibit the proliferation of SP(+) lung cancer stem cells via enhancing the expressions of miR-32*, miR-466i-5p, and mmu-miR-669c. These might be the mechanism and therapeutic targets of Shuanghuang Shengbai granule. |
format | Online Article Text |
id | pubmed-5617494 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-56174942017-10-03 Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs Wang, Shuang Xu, Zhenye Wang, Lifang Oncotarget Research Paper BACKGROUND: Shuanghuang Shengbai granule is effective in curing cyclophosphamide-induced myelosuppression without promoting lung cancer development. This study aims to investigate its mechanism and therapeutic targets. METHODS: Nude mice with lung cancer were treated with physiological saline (control), cyclophosphamide, or cyclophosphamide + Shuanghuang Shengbai. MicroRNA microarray was used to investigate the differentially expressed microRNAs in lung cancer stem cells or bone marrow hematopoietic stem cells between the three groups. MicroRNA expressions were confirmed using quantitative real time-polymerase chain reaction. RESULTS: Cyclophosphamide suppressed tumor growth and decreased the ratio of SP(+) lung cancer stem cells (P<0.05). Shuanghuang Shengbai further decreased the ratios of SP(+) and CD24(+)IGF1R(+) lung cancer stem cells (P<0.05). Shuanghuang Shengbai completely reversed the cyclophosphamide-induced decreases in white blood cells, proliferation index of bone marrow cells, and the ratio of CD34(+)SCA1(+) bone marrow hematopoietic stem cells (P<0.05). We found 45 and 343 altered microRNAs for SP(+) lung cancer stem cells and CD34(+)SCA1(+) bone marrow hematopoietic stem cells, respectively. Moreover, miR-32*, miR-466i-5p, and mmu-miR-669c in SP(+) lung cancer stem cells were confirmed, as well as mmu-miR-106b*, mmu-miR-144, mmu-miR-669k*, mmu-miR-142-3p, mmu-miR-210, and mmu-miR-223 in CD34(+)SCA1(+) bone marrow hematopoietic stem cells. CONCLUSION: Shuanghuang Shengbai might promote the proliferation of CD34(+)SCA1(+) bone marrow hematopoietic stem cells via up-regulating mmu-miR-106b*, mmu-miR-144, and mmu-miR-669k*, as well as down-regulating mmu-miR-142-3p, mmu-miR-210, and mmu-miR-223. Shuanghuang Shengbai might further inhibit the proliferation of SP(+) lung cancer stem cells via enhancing the expressions of miR-32*, miR-466i-5p, and mmu-miR-669c. These might be the mechanism and therapeutic targets of Shuanghuang Shengbai granule. Impact Journals LLC 2017-07-10 /pmc/articles/PMC5617494/ /pubmed/28977934 http://dx.doi.org/10.18632/oncotarget.19129 Text en Copyright: © 2017 Wang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Wang, Shuang Xu, Zhenye Wang, Lifang Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs |
title | Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs |
title_full | Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs |
title_fullStr | Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs |
title_full_unstemmed | Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs |
title_short | Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs |
title_sort | shuanghuang shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of micrornas |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617494/ https://www.ncbi.nlm.nih.gov/pubmed/28977934 http://dx.doi.org/10.18632/oncotarget.19129 |
work_keys_str_mv | AT wangshuang shuanghuangshengbaigranulecuresmyelosuppressionandsuppresseslungcancerprogressionmechanismandtherapeutictargetsfromtheaspectofmicrornas AT xuzhenye shuanghuangshengbaigranulecuresmyelosuppressionandsuppresseslungcancerprogressionmechanismandtherapeutictargetsfromtheaspectofmicrornas AT wanglifang shuanghuangshengbaigranulecuresmyelosuppressionandsuppresseslungcancerprogressionmechanismandtherapeutictargetsfromtheaspectofmicrornas |